Alphabet Inc. Acquires Shares of 2,412,471 Maze Therapeutics, Inc. (NASDAQ:MAZE)

Alphabet Inc. acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 2,412,471 shares of the company's stock, valued at approximately $26,561,000. Maze Therapeutics makes up 1.7% of Alphabet Inc.'s holdings, making the stock its 13th largest holding. Alphabet Inc. owned approximately 5.51% of Maze Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics in the 1st quarter worth $11,405,000. Bessemer Group Inc. purchased a new position in shares of Maze Therapeutics during the first quarter valued at $5,305,000. Bank of New York Mellon Corp purchased a new position in shares of Maze Therapeutics during the first quarter valued at $190,000. Finally, New York State Common Retirement Fund purchased a new position in Maze Therapeutics in the first quarter valued at about $25,000.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wedbush began coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $23.50.

Maze Therapeutics Stock Up 1.7%

Maze Therapeutics stock traded up $0.27 during trading hours on Tuesday, hitting $16.01. The stock had a trading volume of 89,289 shares, compared to its average volume of 120,422. The company's 50-day simple moving average is $11.89. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $17.00.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.